Genomic marker predicts anti-PD-1 response in several cancers

Bookmark and Share
Published: 29 May 2015
Views: 2278
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Dr Le talks to ecancertv at ASCO 2015 about a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.

Read the news article or watch the press conference video for more.